Spero Common Stock Shares Outstanding from 2010 to 2026
| SPRO Stock | USD 2.14 0.09 4.04% |
Common Stock Shares Outstanding | First Reported 2016-09-30 | Previous Quarter 56 M | Current Value 56.3 M | Quarterly Volatility 17.6 M |
Check Spero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spero Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 5.7 M, Depreciation And Amortization of 2.2 K or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 1.27, Dividend Yield of 0.0031 or PTB Ratio of 1.32. Spero financial statements analysis is a perfect complement when working with Spero Therapeutics Valuation or Volatility modules.
Spero | Common Stock Shares Outstanding | Build AI portfolio with Spero Stock |
Evaluating Spero Therapeutics's Common Stock Shares Outstanding across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Spero Therapeutics's fundamental strength.
Latest Spero Therapeutics' Common Stock Shares Outstanding Growth Pattern
Below is the plot of the Common Stock Shares Outstanding of Spero Therapeutics over the last few years. It is the total number of shares of a company's common stock that are currently owned by all its shareholders. Spero Therapeutics' Common Stock Shares Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spero Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Shares Outstanding | 10 Years Trend |
|
Common Stock Shares Outstanding |
| Timeline |
Spero Common Stock Shares Outstanding Regression Statistics
| Arithmetic Mean | 24,015,956 | |
| Geometric Mean | 15,207,243 | |
| Coefficient Of Variation | 91.99 | |
| Mean Deviation | 18,683,110 | |
| Median | 16,001,832 | |
| Standard Deviation | 22,091,637 | |
| Sample Variance | 488T | |
| Range | 62.7M | |
| R-Value | 0.91 | |
| Mean Square Error | 92.6T | |
| R-Squared | 0.82 | |
| Slope | 3,966,640 | |
| Total Sum of Squares | 7808.6T |
Spero Common Stock Shares Outstanding History
About Spero Therapeutics Financial Statements
Spero Therapeutics investors utilize fundamental indicators, such as Common Stock Shares Outstanding, to predict how Spero Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 62.1 M | 65.3 M |
Pair Trading with Spero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Spero Stock
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Spero Therapeutics Correlation against competitors. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could Spero diversify its offerings? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spero Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.753 | Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets |
Understanding Spero Therapeutics requires distinguishing between market price and book value, where the latter reflects Spero's accounting equity. The concept of intrinsic value—what Spero Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spero Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spero Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.